Saturday 17 October 2026 Export VTGN’s income statement to Excel — free account

VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.

0.20 0.01 −4.76%

Follow VTGN

Alert me

Market cap: $9.5M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: 3/9
Altman Z: −16.79
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 9.45

Revenue 2.50

Net Income (67.62)

Free Cash Flow (62.30)

Net Debt (31.73)

Current Ratio 3.07

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.53)

P/S ratio 3.44

P/B ratio 0.35

Past 5Y EPS Growth —

This Y EPS Growth 19.40%

Next Y EPS Growth (4.41%)

Next Y revenue growth 33.96%

Next 5Y EPS Growth 3.20%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.05%

10-year low 10-year high

P/B against its own 10 years 0.05%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	119	80	45	32
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	121	82	47	34

	2024	2025	2026	Q'26
Payables	2	1	2	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	5	13	13	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.10%	0.00%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(17.33%)	43.26%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	1	—	—	—	—
’26	0	0	0	0	1
’25	0	0	0	0	0
’24	0	0	0	0	1
’23	0	(1)	0	0	0
’22	0	0	0	0	1
’21	—	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(15)	—	—	—	—
’26	(19)	(14)	(18)	(16)	(66)
’25	(11)	(11)	(10)	(10)	(42)
’24	(8)	(6)	(5)	(7)	(26)
’23	(16)	(16)	(10)	(7)	(50)
’22	(6)	(11)	(12)	(16)	(45)
’21	(3)	1	(5)	(5)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(15)	—	—	—	—
’26	(19)	(14)	(18)	(16)	(67)
’25	(11)	(11)	(10)	(10)	(42)
’24	(8)	(6)	(5)	(7)	(26)
’23	(16)	(16)	(10)	(7)	(50)
’22	(6)	(12)	(12)	(16)	(45)
’21	(3)	1	(5)	(5)	(12)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(0.30)	—	—	—	—
’26	(0.47)	(0.54)	(0.45)	(0.37)	(1.83)
’25	(0.35)	(0.42)	(0.46)	(0.43)	(1.67)
’24	(0.94)	(0.66)	(0.22)	(0.25)	(1.52)
’23	(3.00)	(2.40)	(1.50)	(1.69)	(8.51)
’22	(1.20)	(2.10)	(1.50)	(2.40)	(7.51)
’21	(2.10)	(1.50)	(2.10)	(6.01)	(14.71)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	20.70	24.30	8.70	9.00	48.00	2.40	1.62	2.22	0.63	0.20	Analyst estimates 2027–2029 Powerpack
	High	117.00	73.20	55.80	58.80	106.50	63.30	24.71	5.86	5.14	0.80
People
People	Employees	9	9	9	9	21	36	34	40	57	41
	Revenue/emp, $m	0.14	0.00	0.00	0.00	0.05	0.03	(0.01)	0.03	0.01	0.03
Income, $m
Income, $m	Revenue	1	—	—	—	1	1	0	1	0	1
	Gross margin, %	100.00	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(10)	(14)	(25)	(21)	(18)	(48)	(59)	(29)	(51)	(70)
	EBT margin, %	(820.25)	0.00	0.00	0.00	(1,645.86)	(4,306.88)	26,097.80	(2,759.21)	(10,578.40)	(5,490.78)
	Net income	(10)	(14)	(25)	(21)	(18)	(48)	(59)	(29)	(51)	(70)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	4.98	0.00	0.00	0.00	0.38	0.17	(0.03)	0.06	0.02	0.03
	Earnings	(46.25)	(33.63)	(27.03)	(15.01)	(14.71)	(7.51)	(8.51)	(1.52)	(1.67)	(1.83)
	Cash flow	(28.96)	(19.59)	(15.27)	(10.79)	(4.21)	(6.86)	(7.14)	(1.33)	(1.36)	(1.74)
	Capex	(0.95)	0.00	(0.18)	0.00	(0.10)	(0.03)	(0.03)	0.00	(0.01)	0.00
	Free cash flow	(29.91)	(19.59)	(15.46)	(10.79)	(4.31)	(6.89)	(7.17)	(1.34)	(1.37)	(1.75)
	Book value	2.46	14.95	7.44	(3.92)	32.07	9.81	1.74	5.90	2.28	0.93
	Shares, m	0	0	1	1	3	7	7	19	31	38
Valuation, ×
Valuation, ×	P/E	0.00	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	7.67	—	—	—	78.34	221.39	0.00	98.23	158.83	17.10
	P/B	24.10	—	—	—	1.99	3.79	2.07	0.91	1.10	0.61
	EV/Sales	10.48	—	—	—	39.25	169.78	(73.68)	(5.96)	10.33	(12.13)
	EV/FCF	(2.69)	—	—	—	(7.43)	(4.14)	(0.33)	0.25	(0.12)	0.23
Cash, $m
Cash, $m	Operating cash flow	(7)	(9)	(15)	(16)	(12)	(45)	(50)	(26)	(42)	(66)
	Capex	0	0	0	—	0	0	0	0	0	0
	Free cash flow	(8)	(9)	(15)	(16)	(12)	(45)	(50)	(26)	(42)	(67)
Balance, $m
Balance, $m	Working capital	2	10	11	(1)	100	65	13	116	69	34
	Total debt	0	0	0	0	4	3	1	—	—	—
	Net debt	(3)	(10)	(13)	(1)	(103)	(68)	(17)	(119)	(80)	(45)
	Shareholders’ equity	1	7	7	(6)	92	65	12	114	70	36
Returns, %
Returns, %	ROA	(494.41)	(207.80)	(203.48)	(222.78)	(74.21)	(53.25)	(123.78)	(40.57)	(49.44)	(104.86)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	980.11	(414.00)	(367.99)	(3,294.60)	(98.14)	(62.17)	(154.30)	(46.47)	(55.68)	(131.59)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LTRN Lantern Pharma Inc.	$10.0M	— (loss-making)	—	—	n/m	+25.31% (above 0%: growing)	0.00%	0.00%	Compare
TOVX Theriva Biologics, Inc.	$9.7M	0.1×	—	+33.08% (above 0%: growing)	n/m	+34.69% (above 0%: growing)	100.00%	0.00%	Compare
BIVI BioVie Inc.	$9.6M	— (loss-making)	—	—	n/m	+26.50% (above 0%: growing)	0.00%	0.00%	Compare
LSTA Lisata Therapeutics, Inc.	$9.6M	— (loss-making)	— (loss-making)	−98.30% (below 0%: shrinking)	n/m	+33.04% (above 0%: growing)	100.00%	0.00%	Compare
VTGN VistaGen Therapeutics, Inc.	$9.5M	— (loss-making)	— (loss-making)	+504.92% (above 0%: growing)	n/m	+22.23% (above 0%: growing)	100.00%	(904.34%)
CMMB Chemomab Therapeutics Ltd. Sponsored ADR	$9.4M	— (loss-making)	—	—	n/m	+47.89% (above 0%: growing)	0.00%	0.00%	Compare
MTVA MetaVia Inc.	$9.0M	— (loss-making)	—	—	n/m	−22.42% (below 0%: shrinking)	—	0.00%	Compare
JAGX Jaguar Animal Health, Inc.	$8.9M	0.0×	— (loss-making)	−58.88% (below 0%: shrinking)	n/m	+13.83% (above 0%: growing)	15.84%	(620.16%)	Compare
NKGN NKGen Biotech, Inc.	$8.8M	— (loss-making)	—	—	n/m	+28.68% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$9.5M	—	—	−58.88%	—	+27.59%	15.84%	0.00%

All 614 Biotechnology stocks →

VistaGen Therapeutics, Inc. (VTGN) key facts

Strength: VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025.
VistaGen Therapeutics, Inc. (VTGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VTGN traded at $0.20, a market capitalization of $9.5 million.
Return on equity was −131.6% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −16.79 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.